Indeed, a stage-specific and opposite function for EZH2 at the early and late stages of the disease was suggested; EZH2 acted as a tumor suppressor at the stage of AML induction, while it exerted an oncogenic function during leukemia maintenance (111). Here, EZH2 is linked to acute myeloid leukemia.